This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Prepandrix (with AS03 adjuvant)
Drug Names(s): H5N1 (Avian Flu) Vaccine, H5N1 Vaccine (GSK), Pumarix (EU), Q-Pan H5N1, Adjupanrix
Prepandrix is a prepandemic H5N1 (bird flu) vaccine made from inactivated (killed) H5N1 virus, using the AS03 adjuvant (squalene, DL-a-tocopherol, and polysorbate 80). The prepandemic strategy involves using the prepandemic vaccine to protect against a strain of flu that may cause a future pandemic, without actually knowing the strain ultimately responsible for the pandemic (where cross-protection may help). Prepandrix was originally approved on the basis of H5N1 data using the Vietnam strain. The use of GSK's proprietary AS03 adjuvant allows for a very low antigen dose to be used. Following a Scandanavian outbreak of narcolepsy in association with the administration of another AS03-containing vaccine (Pandremix), anti-AS03 antibodies were identified in approximately one quarter of affected individuals.
Both Prepandrix and Pumarix contain the AS03 adjuvant and the active antigen, A/Indonesia/05/2005 (H5N1).
Prepandrix (with AS03 adjuvant) News
Additional information available to subscribers only: